Sangamo (NASDAQ: SGMO) CLO awarded 800,000 options at $0.2601

Q: How many Sangamo (SGMO) shares are covered by Scott Willoughby’s stock option grant?

The stock option grant covers 800,000 shares of Sangamo Therapeutics common stock. These options increase his potential equity exposure but only become actual shares if he chooses to exercise them after they vest and before expiration.

Q: What is the vesting schedule for the 800,000 Sangamo (SGMO) stock options?

One quarter of the 800,000 stock options will vest and become exercisable on the first anniversary of the grant date. The remaining options then vest in 24 equal monthly installments , conditioned on Scott Willoughby’s continuous service with Sangamo Therapeutics.

Q: Does this Sangamo (SGMO) Form 4 show an insider buying or selling shares on the market?

No, the Form 4 reflects a grant of stock options to Scott B. Willoughby, not an open-market trade. It records a compensation award that gives him the right to buy shares later, rather than a current purchase or sale in the market.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Sangamo Therapeutics reported that SVP and Chief Legal Officer Scott B. Willoughby received a grant of stock options covering 800,000 shares of common stock. The options have an exercise price of $0.2601 per share and expire on March 31, 2036.

These options were granted as compensation and do not represent an open-market purchase or sale. One quarter of the options will vest after one year from the grant date, with the remaining shares vesting in 24 equal monthly installments, contingent on his continued service under the company’s 2018 equity incentive plan.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Willoughby Scott B.

Role SVP, CHIEF LEGAL OFFICER, SECY

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	800,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 800,000 shares (Direct)

Footnotes (1)

[object Object]

Key Figures

Option grant size: 800,000 options Exercise price: $0.2601 per share Underlying shares: 800,000 shares +4 more

7 metrics

Option grant size 800,000 options Stock Option (Right to Buy) awarded to SVP, CLO

Exercise price $0.2601 per share Conversion or exercise price of granted options

Underlying shares 800,000 shares Common stock underlying the derivative award

Shares after grant 800,000 options Total derivative securities following transaction

Expiration date March 31, 2036 Option expiration for this grant

Initial vesting 25% at 1-year anniversary One quarter vests after first year of grant

Ongoing vesting 24 monthly installments Remaining options vest monthly after first anniversary

Key Terms

Stock Option (Right to Buy), 2018 EIP, Continuous Service, vest, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

2018 EIP financial

"as provided in the 2018 EIP."

Continuous Service financial

"subject to the Reporting Person's Continuous Service"

vest financial

"the shares subject to the option will vest and become exercisable"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercise price financial

"conversion_or_exercise_price: 0.2601"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Form 4 Insider Transactions: What Each Field Means →

04/03/2026 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Willoughby Scott B.

(Last)

(First)

(Middle)

C/O SANGAMO THERAPEUTICS, INC.

501 CANAL BLVD.

(Street)

RICHMOND

CALIFORNIA

94084

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SANGAMO THERAPEUTICS, INC [ SGMO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, CHIEF LEGAL OFFICER, SECY

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$0.2601	04/01/2026		A		800,000		⁽¹⁾	03/31/2036	Common Stock	800,000	$0	800,000	D

Explanation of Responses:

1. One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

	/s/ Scott Willoughby	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Sangamo Therapeutics (SGMO) report for Scott B. Willoughby?

Sangamo Therapeutics reported that SVP and Chief Legal Officer Scott B. Willoughby received a grant of stock options for 800,000 shares. These options are a compensation award rather than an open-market stock purchase or sale, and give him the right to buy SGMO common shares at a fixed price.

What is the exercise price of the new stock options granted at Sangamo (SGMO)?

The newly granted stock options for Scott B. Willoughby carry an exercise price of $0.2601 per share. This means he can buy SGMO common stock at $0.2601 once the options vest, regardless of the market price at that time.

How many Sangamo (SGMO) shares are covered by Scott Willoughby’s stock option grant?

The stock option grant covers 800,000 shares of Sangamo Therapeutics common stock. These options increase his potential equity exposure but only become actual shares if he chooses to exercise them after they vest and before expiration.

What is the vesting schedule for the 800,000 Sangamo (SGMO) stock options?

One quarter of the 800,000 stock options will vest and become exercisable on the first anniversary of the grant date. The remaining options then vest in 24 equal monthly installments, conditioned on Scott Willoughby’s continuous service with Sangamo Therapeutics.

When do Scott Willoughby’s Sangamo (SGMO) stock options expire?

The granted stock options held by Scott B. Willoughby expire on March 31, 2036. He must exercise vested options before that expiration date; otherwise, any unexercised options will lapse and no longer provide the right to purchase SGMO shares.

Does this Sangamo (SGMO) Form 4 show an insider buying or selling shares on the market?

No, the Form 4 reflects a grant of stock options to Scott B. Willoughby, not an open-market trade. It records a compensation award that gives him the right to buy shares later, rather than a current purchase or sale in the market.